LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 20.9% in August

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 45,400 shares, a decline of 20.9% from the August 15th total of 57,400 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 69,300 shares, the days-to-cover ratio is currently 0.7 days.

LAVA Therapeutics Trading Up 2.6 %

Shares of LAVA Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, hitting $1.76. The stock had a trading volume of 45,694 shares, compared to its average volume of 684,267. The firm has a 50-day moving average of $1.86 and a two-hundred day moving average of $2.37. The firm has a market cap of $44.62 million, a P/E ratio of -1.63 and a beta of 0.51. The company has a quick ratio of 6.39, a current ratio of 6.39 and a debt-to-equity ratio of 0.01. LAVA Therapeutics has a 12-month low of $1.13 and a 12-month high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative return on equity of 48.53% and a negative net margin of 228.02%. Sell-side analysts forecast that LAVA Therapeutics will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on LVTX. JMP Securities reiterated a “market outperform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Friday, June 28th.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC purchased a new position in shares of LAVA Therapeutics (NASDAQ:LVTX) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.